Prolensa bromfenac regulatory update

Bausch + Lomb said FDA approved Prolensa bromfenac to treat pain and ocular inflammation following cataract surgery. The product is a once-daily 0.07% topical non-steroidal anti-inflammatory ophthalmic solution and will be available in 1.6 and 3 mL bottles. The company expects to launch the product later this month. ...